LY2886721 in mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease

Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease comparing LY2886721 with Placebo (2 arms). Primary endpoints: Change from baseline to 12 weeks in cerebrospinal fluid amyloid beta 1-40 and amyloid beta 1-42 concentrations and Change from baseline to 26 weeks in cerebrospinal fluid amyloid beta 1-40 and amyloid beta 1-42 concentrations. Started Jun 2012; status: terminated.